Morgan Stanley analyst Judah Frommer has maintained their bullish stance on RGNX stock, giving a Buy rating on September 5.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Judah Frommer’s rating is based on promising data from RegenXBio’s CAMPSIITE study of RGX-121 for MPS II, which showed significant reductions in CSF HS D2S6 levels, a key biomarker, and positive neurodevelopmental outcomes. The data supports the ongoing BLA filing under the accelerated approval pathway, which has been extended to February 2026, indicating potential regulatory progress. Additionally, the safety profile of RGX-121 was favorable, with the treatment being well tolerated among participants. RegenXBio has also secured a substantial upfront payment from Nippon Shinyaku, which enhances its financial position. If RGX-121 receives approval, the company could further benefit from a Priority Review Voucher, potentially extending its cash runway into early 2027.
In another report released on September 5, Raymond James also reiterated a Buy rating on the stock with a $29.00 price target.